How common is life-threatening colitis with Yervoy (ipilimumab)?
Life-threatening colitis is not the most common serious side effect, but it is a known risk. In clinical safety data for ipilimumab (Yervoy), colitis and severe diarrhea can occur as immune-related adverse events, and some cases are severe or life-threatening.[1][2]
Because “life-threatening” is less frequent than any-grade colitis, most patients do not experience it. The key practical point is that colitis can be serious enough to require urgent medical treatment and permanent discontinuation in some cases.[1][2]
What side effects of Yervoy suggest colitis?
Colitis typically shows up as new or worsening gastrointestinal symptoms during treatment, such as diarrhea and abdominal pain, sometimes with blood or mucus in stool. The warning symptoms that raise concern for severe disease include:
- Severe or persistent diarrhea
- Diarrhea with blood
- Significant abdominal pain or cramping
- Dehydration or feeling very unwell
If these occur, clinicians generally treat it as immune-mediated until proven otherwise.[1][2]
When does immune-related colitis usually happen?
Immune-related adverse events from Yervoy can develop after starting treatment and may occur during therapy or after doses, so patients are instructed to report new symptoms promptly rather than waiting for a scheduled visit.[1][2]
Is Yervoy colitis “common” compared with other immune side effects?
Colitis is generally less common than some other immune-related effects (such as skin reactions), but it is clinically important because it can become severe. The overall takeaway from the safety information is that colitis occurs, including severe and life-threatening cases, but most patients do not develop life-threatening disease.[1][2]
What happens if colitis becomes severe or life-threatening?
When colitis is suspected to be severe, treatment typically includes holding Yervoy and starting immune-suppressing therapy (for example, corticosteroids), with escalation if needed depending on severity and response. Serious cases may require inpatient care and additional immunosuppression.[1][2]
What should patients do to reduce risk?
Patients should contact their oncology team right away if they develop significant diarrhea or abdominal pain while taking Yervoy. Early reporting leads to faster evaluation and treatment, which is crucial for preventing progression to severe or life-threatening colitis.[1][2]
Sources cited:
1. YERVOY (ipilimumab) Prescribing Information – Bristol Myers Squibb
2. FDA Label for Yervoy (ipilimumab)